XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

Medtronic lifts profit forecast on medical devices demand, new launches



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Medtronic lifts profit forecast on medical devices demand, new launches</title></head><body>

Adds details on new launches in paragraphs 4-6, details on segment revenue in paragraphs 9 and 10

Aug 20 (Reuters) -Medtronic MDT.N slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growthfrom its new launches.

Over the past few quarters, medicaldevice makers have been benefiting from elevateddemand for non-urgent surgeries, sincepatients are increasingly optingfor procedures deferred during the pandemic.

The company said it was expecting steady growth as it introduces new products and continues to make investments to support those launches.

Earlier this month, the company said it received FDA approval for its first disposable, all-in-one continuous glucose monitor, Simplera.

Medtronic has partnered with AbbottABT.N, and will integrate its continuous glucose monitoring sensors with Medtronic's insulin delivery systems.

Limited U.S. commercial release of its Evolut FX+ Transcatheter aortic valve replacement device was initiated during the quarter, the company said. The device is used to perform minimally invasive surgery for people with heart valve disease.

The company raised the lower end of its 2025 adjusted profit forecast to$5.42 per share from $5.40 earlier, keeping the upper end at $5.50.

Analysts on average were expecting profit of $5.44 for 2025, according to LSEG data.

Quarterly sales at Medtronic's heart devices unit, its biggest revenue driver, increased 5.5% to $3.01 billion, above analysts' estimate of $2.92 billion.

Sales at the company's diabetes unit, rose nearly 12% while sales at its neuroscience unit, rose 4.4%.

Medtronic posted adjusted profit of $1.23 per share for the first quarter, beating estimates of $1.20.



Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and Alan Barona

</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.